PRPH ProPhase Labs, Inc.
Healthcare$0.11+22.22%ClosedMarket Cap: $521,071
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
0.07
P/S
0.48
EV/EBITDA
-0.31
DCF Value
$-12.72
FCF Yield
-4366.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
191.4%
Operating Margin
-2496.6%
Net Margin
-3872.2%
ROE
-404.4%
ROA
-63.5%
ROIC
-156.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 null | $883.0K | -13.9% | $-4.8M | $-6.8M | $— | — |
| Q2 null | $1.2M | 58.9% | $-3.9M | $-4.5M | $— | — |
| Q1 null | $1.4M | 36.8% | $-3.7M | $4.0M | $— | — |
| Q4 null | $-2.5M | -37.2% | $-14.6M | $-34.4M | $— | — |
| FY null | $6.8M | -2.2% | $-38.6M | $-53.4M | $— | — |
| Q3 null | $3.1M | -5.2% | $-7.9M | $-6.6M | $— | — |
| Q2 null | $2.5M | -19.2% | $-7.8M | $-6.2M | $— | — |
| Q1 null | $3.6M | -11.9% | $-8.3M | $-6.3M | $— | — |
| Q4 null | $3.5M | -87.3% | $-11.4M | $-8.8M | $— | — |
| FY null | $44.4M | 36.6% | $-21.6M | $-16.8M | $— | — |
| Q3 2023 | $8.4M | 27.8% | $-6.5M | $-5.1M | $-3.00 | — |
| Q2 2023 | $13.2M | 48.8% | $-4.7M | $-3.4M | $-2.00 | — |